Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Superior Remedies vs Trimi

Two GLP-1 desks, one scoreboard. We put Superior Remedies and Trimi head-to-head on the published Brief Score — the same six factors, scored the same way.

No. 296 · Grade C

Superior Remedies

Visit Superior Remedies Full brief →
vs
Higher Brief ScoreNo. 2 · Grade B+

Trimi

Visit Trimi Full brief →

The verdict

Trimi takes this head-to-head.

Trimi scores 89 to 62 on our six-factor Brief Score — A clean, all-in membership desk that publishes one price on both molecules nationwide and hasn't played the teaser-rate game.

That doesn't make Superior Remedies a bad call — it's best for readers who want a low-dose protocol designed on its own terms rather than a smaller version of a weight-loss plan, and who do not mind starting an eligibility check to learn the price. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
40
90
Supply Reliability
65
89
Transparency
30
91
Access Breadth
95
89
Clinical Oversight
80
88
Track Record
55
84
Superior RemediesBrief Score 62 · 89Trimi

Price, coverage & the tracker

Superior RemediesTrimi
Brief Score62/100 (C)89/100 (B+)
SemaglutideNot disclosed$175/mo month-to-month · $99/mo only on a 12-month prepay ($1,188 in one charge)
TirzepatideNot disclosed$235/mo month-to-month · $125/mo only on a 12-month prepay ($1,500 in one charge)
CoverageAll 50 states (telehealth nationwide)All 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
On the trackerNewnew to the tracker, no prior readingStableprice stable

Superior Remedies: New to the tracker on 11 August 2026, read on the provider's own site rather than taken on trust: we loaded https://superiorremedies.com/treatments/glp-1-microdose on 2026-08-11 and it publishes no price and no milligram anywhere on the page. The only figure the public site carries is a homepage headline labeled a limited-time offer, attached to the general pitch rather than to any one of its three programs. There is no earlier reading of ours to compare it against yet.

Trimi: Membership rate held flat this cycle — both molecules disclosed up front, no first-month teaser.

Not sold on either?

CoreAge Rx tops the whole ranking at 94/100.

The steadiest desk in the ranking: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.